Back to Peptides

Ara 290

Extensively Studied

Tissue-Protective Peptide | Innate Repair Receptor Agonist

Dose 4 mg daily
Frequency Once daily
Cycle 28 days
Storage Lyophilized: 2-8°C refrigerated, protect from light. Reconstituted: use immediately or refrigerate up to 24 hours
Accumulation Plotter

Ara 290 is an engineered 11-amino acid peptide activating the Innate Repair Receptor (IRR) to provide tissue-protective effects without red blood cell stimulation. Has FDA Orphan Drug status.

Mechanism of Action

Activates IRR through EPOR/β-common receptor complex, triggering tissue-protective signaling without erythropoietic effects.

Key Benefits

  • Proven tissue protection
  • Nerve regeneration
  • Anti-inflammatory effects
  • Excellent safety profile in clinical trials
Molecular Weight
1,257 Da
Chain Length
11 amino acids
Type
Engineered peptide
Amino Acid Sequence
One-letter: ?ELERALNSS
H₂N
H
? 1
O ‖ C
N
E 2
O ‖ C
N
L 3
O ‖ C
N
E 4
O ‖ C
N
R 5
O ‖ C
N
A 6
O ‖ C
N
L 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
S 10
COOH
pGl
1

pGlu

Position 1

Glu
2

Glutamic Acid

Position 2

Leu
3

Leucine

Position 3

Glu
4

Glutamic Acid

Position 4

Arg
5

Arginine

Position 5

Ala
6

Alanine

Position 6

Leu
7

Leucine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Ser
10

Serine

Position 10

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Neuroprotection

  • Peripheral Nerve Regeneration

    23% increase in corneal nerve fiber area with sustained pain improvement.

  • Diabetic Neuropathy Treatment

    Nerve regeneration and metabolic improvements in Type 2 diabetes patients.

  • CNS Protection

    Crosses blood-brain barrier for stroke and TBI neuroprotection.

Tissue Repair

  • Wound Healing

    Improves epithelialization and angiogenesis via VEGF upregulation.

  • Cardiovascular Protection

    Reduces infarct size in myocardial infarction models.

  • Anti-Aging Effects

    Maintains cardiac function in aging models.

Anti-Inflammatory

  • Cytokine Reduction

    Reduces TNF-α, IL-6, and IL-12 production.

  • IBD Support

    Reduces colitis severity in animal models.

  • Transplant Protection

    Improves graft survival and reduces rejection.

Primary clinical administration route with proven efficacy.

GoalDoseFrequencyRoute
Neuropathy Treatment4 mg dailyOnce dailySubQ
Tissue Protection1-8 mg dailyOnce dailySubQ
Acute Intervention2 mg3x weeklyIV

Reconstitution Instructions

Materials Needed:
  • Ara 290 lyophilized powder (4 mg vial)
  • Sterile water for injection
  • Sterile syringes and needles
  • Alcohol swabs
  • Light protection
  1. 1 Allow vial to reach room temperature (15-20 minutes)
  2. 2 Clean vial top with alcohol swab
  3. 3 Slowly inject 1 mL sterile water
  4. 4 Gently swirl to dissolve (no vigorous shaking)
  5. 5 Slight cloudiness is normal
  6. 6 Use immediately or refrigerate up to 24 hours
  7. 7 Protect from light
  8. 8 Rotate injection sites
BPC-157

Complementary tissue repair pathways may enhance wound healing.

synergistic
TB-500

Combined mechanisms enhance recovery from injury.

synergistic
Thymosin Beta-4

No known interactions; different mechanisms for tissue protection.

compatible
EPO

Clinical trials exclude EPO use within 2 months due to receptor interference.

avoid
NAD+

Both affect cellular metabolism; monitor for additive effects.

monitor
Semaglutide

No adverse interactions in clinical trials with GLP-1 agonists.

compatible
Growth Hormone

Both affect tissue repair; requires monitoring for excessive growth factor activity.

monitor
Anti-TNF Biologics

6-month washout required before Ara 290 to avoid immune interactions.

avoid
Week 1-2

Initial anti-inflammatory effects and mild pain symptom improvement

Week 2-4

Progressive nerve regeneration, improved tissue healing markers

Week 4-6

Peak therapeutic effects, maximum nerve fiber density improvements

Month 2-6

Long-lasting benefits via molecular switch effect

Common Side Effects

  • Excellent safety profile in clinical trials with no serious drug-related adverse events

Stop Signs - Discontinue if:

  • Severe injection site reactions
  • Unexpected blood count changes
  • Allergic reaction signs
  • Worsening of underlying condition
  • New neurological symptoms
  • Any serious adverse events

Contraindications

  • Recent anti-TNF therapy (within 6 months)
  • EPO use (within 2 months)
  • Pregnancy
  • BMI > 34 kg/m²

Good Signs

  • Pharmaceutical grade manufacturing with GMP conditions
  • Proper peptide sequence verification - correct 11-amino acid sequence with N-terminal pyroglutamate
  • Sterile lyophilized powder with proper freeze-drying
  • Clinical batch documentation - Purity >95%, endotoxin <1 EU/mg, sterility verified

Warning Signs

  • Light-sensitive formulation - requires protection during storage and use

Bad Signs

  • Cloudy or discolored solution indicates degradation; should be clear to slightly cloudy
  • Sarcoidosis Neuropathy Phase 2b Trial
    (2017)

    64 patients, 1-8 mg SC daily for 28 days: 23% increase in corneal nerve fiber area at 4 mg dose.

  • Type 2 Diabetes Neuropathy Phase 2
    (2015)

    48 patients, 4 mg SC daily for 28 days: Sustained HbA1c improvement and nerve regeneration.

  • Diabetic Macular Edema Pilot Study
    (2020)

    9 patients, 4 mg SC daily for 12 weeks: Improved quality of life; good safety profile.

  • Myocardial Infarction Protection Study
    (2012)

    Preclinical mouse model, 24 μg/kg IV single dose: Reduced infarct size and improved survival.

  • Stroke Neuroprotection Research
    (2011)

    Rat stroke model, 300 μg/kg IV single dose: Reduced stroke volume; BBB penetration confirmed.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.